LGM Pharma Acquires Sannova Analytical
Acquisition adds GLP bioanalysis, genotoxic and nitrosamine impurity testing, and extractables and leachables evaluations.
LGM Pharma
LGM Pharma Boosts US Manufacturing with Additional $9 Million Investment
LGM Pharma invests an additional $9 million to expand US manufacturing, bringing total investment to $15 million across its Texas and Colorado facilities.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
LGM Pharma Buys Nexgen Assets
US API specialist LGM Pharma has acquired the formulation development and drug product contract manufacturing business of specialty pharma company Nexgen Pharma for an undisclosed sum.
